bims-polgdi Biomed News
on POLG disease
Issue of 2026–11–08
27 papers selected by
Luca Bolliger, lxBio



  1. Acta Biochim Biophys Sin (Shanghai). 2026 Nov 06.
      Mitochondrial DNA (mtDNA) mutations constitute major genetic determinants of mitochondrial disorders and contribute to the progressive dysfunction of energy-demanding tissues. However, precise manipulation of the mitochondrial genome remains a formidable challenge for decades due to the unique structural and biological features of mitochondria. Recent breakthroughs in mitochondrial base-editing technologies address longstanding barriers in mitochondrial genome engineering by enabling programmable nucleotide conversion without introducing DNA double-strand breaks. Mitochondrial base editing evolves rapidly from a proof-of-concept strategy in cultured cells into a versatile platform for generating animal models, dissecting mitochondrial gene function and exploring therapeutic interventions for mitochondrial diseases. Recent advances enable the creation of animals carrying defined pathogenic mtDNA variants and provide initial evidence supporting the feasibility of in vivo mitochondrial genome correction and disease amelioration. Here, we review the evolution of mitochondrial base-editing technologies and summarize the major editing platforms, with particular emphasis on recent advances in editor engineering, expansion of targeting capabilities, generation of animal disease models and emerging therapeutic applications. We further discuss the remaining challenges, including editing precision, target-site accessibility, delivery efficiency, and comprehensive safety evaluation. Finally, we highlight future opportunities for developing next-generation mitochondrial genome-editing systems and advancing their translation toward clinical applications.
    Keywords:  base editing; gene editing; mitochondrial disease
    DOI:  https://doi.org/10.3724/abbs.2026192
  2. Curr Gene Ther. 2026 Oct 20.
      Mitochondria are essential structures that produce energy in cells through mitochondrial oxidative phosphorylation and are one of the primary sources of reactive oxygen species (ROS). Mutations in mitochondrial DNA (mtDNA) cause a wide range of hereditary illnesses with multisystem clinical symptoms, poor cellular bioenergetics, and decreased mitochondrial oxidative phosphorylation. Effective treatment approaches have been hampered by the genetic complexity associated with mtDNA disorders, including heteroplasmy and tissue-specific diversity. The relationship between mutations in the mitochondrial DNA and oxidative stress is multidimensional and snowballing, with structural malfunction of the electron transport chain encouraging the development of ROS that causes further damage to mitochondrial DNA, lipids, and proteins. Under carefully regulated experimental conditions, cell-based disease models, in particular induced pluripotent stem cells (iPSCs) and standard transmitochondrial cybrids, have become useful tools for studying disease mechanisms, simulating mutation-specific phenotypes, and assessing possible therapeutic interventions. This review provides the key roles of mutations and oxidative stress in the pathogenesis of the disease in the context of the primary role of the mitochondrial genome, its maternal inheritance, and the most common disorders, i.e., mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and myoclonic epilepsy with ragged red fibers (MERRF). We outline the use of cell-based models to study mitochondrial pathologies, including patient-derived primary cells and iPSCs, which could be differentiated into cell types of interest to the disease, and cybrid systems, which could isolate the contribution of single mutations in the mitochondrial DNA to an underlying background of controlled nuclear genetic backgrounds. Besides, the review focuses on innovative technologies to mend mutations in mitochondrial DNA, such as allotopic expression, mitoTALENs and mitoZFNs, and the new base-editing systems like DdCBEs. Included are the free cell-based therapies like mitochondrial transfer and nuclear transfer procedures. Finally, we discussed the measures to be taken to minimize oxidative stress, and these actions are standard: mitochondria- targeted antioxidants, mitophagy, and autophagy regulation. The study also looks at the present level of proof supporting these therapy techniques and discusses the advantages and disadvantages of existing experimental models. Although several gene editing and mitochondria replacement technologies have shown promising results in clinical and cellular research, their clinical translation is still restricted and needs more confirmation in terms of long-term therapeutic efficacy, safety, and delivery efficiency.
    Keywords:  DdCBEs; Mitochondrial DNA; induced pluripotent stem cells; mtDNA mutation; oxidative stress; reactive oxygen species
    DOI:  https://doi.org/10.2174/0115665232514985261011110951
  3. J Cell Mol Med. 2026 Nov;pii: e71419. [Epub ahead of print]30(21):
      Cellular senescence combines stable cell-cycle arrest with mitochondrial and innate immune remodelling that shapes the senescence-associated secretory phenotype (SASP). This narrative review evaluates mitochondrial dysfunction as a context-dependent initiator or amplifier of senescence and examines mitochondrial DNA (mtDNA) sensing through cGAS-STING as a driver of SASP regulation. We distinguish mitochondrial damage, cytosolic mtDNA exposure, pathway activation, SASP transcription, secretion, paracrine activity and tissue outcomes as separate levels of evidence. The strongest mechanistic studies link BAX/BAK-mediated minority mitochondrial outer-membrane permeabilization, VDAC1 oligomerization, defective mitophagy or abnormal mtDNA composition to cytosolic mtDNA, cGAS-STING activation and SASP modulation through genetic or pharmacological perturbation. However, pathway architecture varies across cell types, tissues and senescence triggers, and nuclear DNA, micronuclei, retroelements and mitochondrial RNA can activate overlapping inflammatory programmes. Preclinical evidence therefore supports STING inhibition primarily as a senomorphic, anti-inflammatory and tissue-protective strategy rather than a senolytic intervention. Mitophagy enhancement, inhibition of mtDNA release, targeted protein degradation and precision delivery offer complementary approaches, but human efficacy remains unestablished. Clinical translation will require standardized biomarkers, biologically informed patient selection, pharmacodynamic confirmation, tissue-restricted or reversible modulation and prospective assessment of antiviral, antitumour and long-term safety. Overall, the mitochondrial dysfunction-mtDNA-cGAS-STING axis is a mechanistically credible but context-dependent therapeutic framework whose clinical value will depend on validated pathway engagement and appropriately timed clinical intervention.
    Keywords:  cGAS–STING signalling; cellular senescence; mitochondrial DNA release; senescence‐associated secretory phenotype; senomorphic therapeutics
    DOI:  https://doi.org/10.1111/jcmm.71419
  4. J Integr Neurosci. 2026 Oct 26. 25(10): 53852
      Huntington's disease (HD) is an inherited neurodegenerative disorder caused by cytosine-adenine-guanine (CAG) repeat expansion in the huntingtin (HTT) gene, resulting in progressive motor, cognitive, and psychiatric impairment. Despite the widespread expression of mutant huntingtin (mHTT), disease progression is characterized by the selective degeneration of striatal neurons. Mitochondrial dysfunction and impaired mitophagy have emerged as important contributors to HD pathogenesis; however, the mechanisms underlying defective mitochondrial quality control remain incompletely understood. Ras homolog enriched in the striatum (Rhes), a small striatal-enriched guanosine triphosphatase (GTPase), has been implicated in mitophagy-related signalling. In this study, we examined the potential relationship between Rhes and PTEN-induced kinase 1 (PINK1)/Parkin-mediated mitophagy in HD. We propose that Rhes contributes to selective striatal vulnerability by promoting mitochondrial depolarization through BCL2 interacting protein 3-like (NIX/BNIP3L), facilitating activation of the PINK1/Parkin mitophagy pathway, while enhancing autophagosome biogenesis through Beclin-1 signalling. If validated, our proposed pathway would open new avenues for therapeutic development in HD.
    Keywords:  Huntington disease; autophagy; huntingtin protein; mitochondria; mitochondrial diseases; mitophagy; neurodegenerative diseases; neurons; proteins; ubiquitination
    DOI:  https://doi.org/10.31083/JIN53852
  5. Nihon Yakurigaku Zasshi. 2026 ;161(6): 416-421
      Bipolar disorder is a severe psychiatric disorder characterized by recurrent episodes of mania and depression. Although several mood stabilizers are available, their mechanisms of action remain incompletely understood, and no drugs have been developed based on the biological abnormalities underlying bipolar disorder. Accumulating evidence, including abnormalities in brain energy metabolism, mitochondrial DNA alterations, and the high prevalence of bipolar disorder among patients with mitochondrial diseases, has led to the mitochondrial dysfunction hypothesis of bipolar disorder. In addition, dysregulation of intracellular Ca2+ signaling has been repeatedly reported in patients with bipolar disorder, suggesting a potential role of mitochondrial calcium homeostasis in the pathophysiology of bipolar disorder. To explore novel therapeutic strategies, we focused on the mitochondrial permeability transition pore (mPTP), a key regulator linking mitochondrial calcium homeostasis and mitochondrial dysfunction. Previous studies using a mutant Polg1 transgenic mouse model, which accumulates mitochondrial DNA abnormalities in the brain, identified cyclophilin D (CypD: PPIF), a regulator of mPTP opening, as a potential therapeutic target. Pharmacological inhibition of CypD improved behavioral abnormalities in this model, supporting the therapeutic relevance of mPTP. Subsequently, an ex vivo screening system using isolated mouse brain mitochondria was established to identify compounds that inhibit mPTP opening. This approach led to the identification of seco-cycline D (SCD), an inhibitor of mPTP opening that also exhibited neuroprotective effects in a mouse model of cerebral ischemia. This review summarizes the rationale for targeting mitochondrial calcium regulation and discusses the potential of mPTP as a novel target for mood stabilizer development.
    DOI:  https://doi.org/10.1254/fpj.26063
  6. Front Neurol. 2026 ;17 1959745
      Central nervous system (CNS) disorders encompass a diverse spectrum of conditions characterized by intricate pathological mechanisms, and the presence of the blood-brain barrier (BBB) has long impeded early diagnosis. Extracellular vesicles (EVs) are lipid bilayer nanoparticles released by living cells that can encapsulate and transport bioactive molecules such as proteins and nucleic acids across the BBB. EVs can be detected in biofluids such as blood and cerebrospinal fluid (CSF) through non-invasive or minimally invasive assays, and have emerged as highly promising vehicles for CNS liquid biopsies. Recent studies demonstrate that specific EV-associated protein cargoes (e.g., phosphorylated tau, α-syn) and non-coding RNAs (e.g., miR-422a, miR-409-3p) exhibit distinct differential expression profiles across various pathologies. These molecular signatures hold promise for early detection, differential diagnosis, and disease staging, with some biomarker panels showing high diagnostic accuracy. However, whether they outperform conventional CSF biomarkers still requires direct comparison and validation within the same cohorts. This review highlights recent research advances in the use of EVs for the diagnosis of Alzheimer's disease and Parkinson's disease, briefly touches upon other CNS disorders including stroke, glioma, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis, and discusses the clinical translational potential and remaining challenges of EV-based diagnostics.
    Keywords:  Alzheimer’s disease; Parkinson’s disease; biomarkers; central nervous system diseases; early diagnosis; extracellular vesicles
    DOI:  https://doi.org/10.3389/fneur.2026.1959745
  7. J Inherit Metab Dis. 2026 Nov;pii: e70262. [Epub ahead of print]49(6):
      Nucleic acid therapeutics (NATs), including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), messenger RNA (mRNA) therapeutics and programmable editing technologies, are reshaping the therapeutic landscape for inherited metabolic and genetic disease. Unlike conventional small molecules or biologics, NATs enable sequence-directed modulation of target gene expression and therefore provide unprecedented flexibility for targeting pathogenic mechanisms previously considered undruggable. Recent clinical successes have established proof of concept for multiple NAT modalities across neurological, hepatic, muscular and metabolic disorders. However, broader implementation remains constrained by challenges in tissue-specific delivery, biomarker validation, natural-history infrastructure and evidence generation in ultra-rare populations. In parallel, increasing platform reproducibility is beginning to challenge traditional product-based regulatory paradigms. This review examines the principal classes of NATs and proposes a practical framework for modality selection based on disease biology, tissue accessibility, durability, reversibility and clinical context. We discuss key translational bottlenecks beyond delivery, including biomarker-outcome relationships, small-population trial design and the limitations of conventional evidentiary frameworks in rare disease. A central theme of this review is the growing transition from isolated precision medicines towards increasingly programmable therapeutic platforms. We explore how advances in extrahepatic delivery, computational oligonucleotide design, artificial intelligence-assisted optimisation and programmable editing technologies may progressively support more scalable and individualised therapeutic development. Finally, we discuss emerging regulatory frameworks that may better accommodate platform-level predictability while maintaining rigorous evaluation of sequence-specific and disease-specific risks.
    Keywords:  RNA interference; antisense oligonucleotides; gene editing; individualised therapy; mRNA therapeutics; nucleic acid therapeutics; precision medicine; rare disease
    DOI:  https://doi.org/10.1002/jimd.70262
  8. J Inflamm Res. 2026 ;19 653025
      Neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) place substantial burden on global public health. Mounting evidence identifies mitochondrial dysfunction as a central contributor to neuronal damage and progressive brain functional decline. As a narrative review, this work aims to dissect mitochondrial‑associated pathological features across these major neurodegenerative disorders, summarize under‑recognized emerging mechanisms, and highlight translational bottlenecks for mitochondrial‑targeted therapies. Mitochondria sustain neuronal survival by mediating oxidative‑phosphorylation‑driven energy production, biomolecule biosynthesis, calcium homeostasis, reactive oxygen species (ROS) metabolism, and apoptotic regulation. In PD, aggregated α‑synuclein (α‑syn) damages respiratory‑chain complex I, perturbs mitochondrial dynamics and blocks PINK1/Parkin‑dependent mitophagy. In AD, amyloid‑β together with hyper‑phosphorylated tau (p-Tau) impairs respiratory complex activity, axonal mitochondrial trafficking and mitophagic clearance. Mutant huntingtin induces multiple mitochondrial lesions in HD, while inflammation‑triggered oxidative stress secondarily compromises mitochondrial function in MS. Pathogenic mutations in ALS disrupt respiratory‑chain assembly, mitochondrial dynamics and mitophagy. Beyond classic mitochondrial defects including respiratory‑chain impairment, dynamic imbalance and defective mitophagy, emerging mechanisms such as mitocytosis, mitochondrial aminoacyl‑tRNA synthetase (mt‑aaRS) dysfunction and mitochondria‑associated membrane (MAM) disruption are discussed. Mitochondrial dysfunction drives neurodegeneration via energy exhaustion, aggravated oxidative stress, pathological protein aggregation and excessive neuronal apoptosis. We further recapitulate mitochondrial‑oriented therapeutic approaches including small‑molecule regulators, mitophagy activators, mitochondrial biogenesis promoters, gene‑editing strategies and mitochondrial transplantation. Notable translational obstacles remain, including limited blood‑brain‑barrier penetration of candidate drugs, narrow therapeutic time‑window post‑symptom onset, and prominent disease heterogeneity. By synthesizing basic experimental findings and pre‑clinical and clinical trial progress, this review provides updated insights into the pathogenesis of neurodegenerative diseases and facilitates the development of precise mitochondrial‑targeted therapeutic regimens.
    Keywords:  mitochondrial dysfunctions; neurodegenerative diseases; neuronal degeneration; oxidative stress; treatment
    DOI:  https://doi.org/10.2147/JIR.S653025
  9. Orphanet J Rare Dis. 2026 08 05. pii: 394. [Epub ahead of print]21(1):
       BACKGROUND: Health technology assessment (HTA) is widely used to inform coverage and reimbursement decisions in health systems by integrating evidence on clinical effectiveness, safety, cost-effectiveness, and broader social considerations. However, the application of conventional HTA frameworks to rare diseases remains challenging due to limited clinical evidence, substantial uncertainty, and ongoing debates regarding the appropriateness of standard evaluation criteria. In this context, this study aimed to identify and synthesize additional criteria and their underlying justifications proposed and/or applied in HTA-based decision-making for rare diseases, and to examine the extent to which these criteria have been adopted by HTA agencies across countries.
    METHODS: The protocol was registered in PROSPERO (CRD420251115351). We conducted an overview of reviews in accordance with the Cochrane Handbook and the PRIOR statement, complemented by a structured grey literature search of health technology assessment agencies and Ministries of Health affiliated with INAHTA and RedETSA. Systematic and scoping reviews, as well as institutional documents addressing criteria used in coverage decisions for rare diseases, were included. Findings were synthesized narratively, with criteria grouped into adapted standard and additional categories, and implementation patterns examined across different health system types.
    RESULTS: Seventeen reviews and multiple institutional documents from eleven countries were included. Seven standard health technology assessment criteria and ten additional criteria were identified. Most jurisdictions reported adaptations of conventional health technology assessment approaches to address uncertainty and ethical concerns associated with rare diseases; however, only a limited number had operationalized a comprehensive set of additional criteria. Disease severity and therapeutic advantage were the most frequently applied additional criteria across countries, whereas treatment characteristics and risk-sharing mechanisms were inconsistently reported. Evidence specific to ultrarare diseases was scarcer, suggesting that decision-making for ultrarare conditions likely relies on criteria applied to rare diseases.
    CONCLUSIONS: Health technology assessment for rare and ultrarare diseases is characterized by selective and pragmatic adaptations rather than the use of unified alternative frameworks.
    REGISTRATION: PROSPERO CRD420251115351.
    Keywords:  Decision making; Health equity; Health policy; Health technology assessment; Patient navigation; Rare diseases; Ultrarare diseases
    DOI:  https://doi.org/10.1186/s13023-026-04521-0
  10. Neurologist. 2026 Nov 02.
       INTRODUCTION: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a clinically and genetically heterogeneous mitochondrial disorder. Although the m.3243A>G variant in MT-TL1 is the most common molecular cause, atypical cases with negative routine genetic testing and nondiagnostic muscle biopsy may pose a substantial diagnostic challenge. Here, we report a clinically diagnosed MELAS case with supportive neuropathological findings and a large-scale deletion involving MT-ND2.
    CASE REPORT: A 20-year-old man presented with recurrent seizures and encephalopathic episodes over 1.5 years. His clinical course was characterized by episodic visual disturbance, hearing impairment, hemiparesis, and progressive encephalopathic deterioration. Serial magnetic resonance imaging revealed recurrent migratory cortical lesions involving the occipital, temporal, and frontal lobes, and magnetic resonance spectroscopy demonstrated a lactate peak. Cerebrospinal fluid analysis and autoimmune and infectious investigations were unremarkable. Electromyography, muscle biopsy, and initial next-generation sequencing, including testing for the common m.3243A>G variant, were nondiagnostic. Subsequent brain biopsy demonstrated laminar cortical necrosis, supporting a mitochondrial encephalopathic process. Multiplex ligation-dependent probe amplification further identified a large-scale pathogenic deletion involving MT-ND2. Based on the characteristic clinical course, neuroimaging pattern, neuropathological findings, and complementary genetic analysis, a diagnosis of MELAS was established.
    CONCLUSION: This case expands the diagnostic spectrum of MELAS and highlights that typical clinical and radiologic features may still be present even when routine lactate testing, muscle biopsy, and standard genetic screening are nondiagnostic. In highly suspected cases, brain biopsy and complementary methods for mitochondrial structural variation analysis, such as MLPA, may provide crucial diagnostic evidence.
    Keywords:  MELAS; MLPA; MT-ND2; brain biopsy; stroke-like episodes
    DOI:  https://doi.org/10.1097/NRL.0000000000000699
  11. Microbiol Spectr. 2026 Nov 03. e0228326
      Atp12 is known as a chaperone for mitochondrial ATP synthase assembly, yet its functions and mechanisms in regulating mitochondrial and cellular aging remain elusive. In this study, we demonstrate that Atp12 plays a critical role in regulating mitochondrial dynamics and chronological lifespan (CLS) in the fission yeast Schizosaccharomyces pombe. We found that Atp12 localizes to mitochondria, and its deletion leads to severe mitochondrial fragmentation, reduced complex II activity, dissipation of mitochondrial membrane potential, and a marked shortening of CLS. Mechanistically, Atp12 acts partially independently of ATP synthase, as the Δatp12Δatp1 double mutant exhibited more severe defects in mitochondrial function and viability than either single mutant, and its mitochondrial morphology resembled that of Δatp12 rather than Δatp1. Transcriptomic and phenotypic analyses identified Fzo1, a mitofusin essential for mitochondrial fusion, as a key downstream target of Atp12 in regulating cellular aging. Further analysis revealed that Atp12 physically interacts with Fzo1 and stabilizes its protein levels. Genetic epistasis experiments demonstrated that Fzo1 insufficiency largely accounts for the mitochondrial fragmentation and functional decline observed in Δatp12 cells, as Fzo1 overexpression effectively rescues these defects. Collectively, these findings uncover a novel function of Atp12 in maintaining mitochondrial homeostasis and delaying cellular aging by stabilizing the mitochondrial fusion machinery. Given the evolutionary conservation of Atp12 from yeast to humans, this study provides a mechanistic framework for understanding how the coordination of mitochondrial biogenesis and dynamics drives the aging process.IMPORTANCEMitochondrial dysfunction is a hallmark of cellular aging, but how mitochondria are regulated at the molecular level to influence cellular longevity remains elusive. Here, we reveal that Atp12, a conserved chaperone for ATP synthase assembly, also serves as a stabilizer of the mitofusin Fzo1 to preserve mitochondrial fusion and chronological lifespan in fission yeast. Through direct physical interaction, Atp12 sustains Fzo1 protein levels, thereby maintaining mitochondrial morphology, respiratory function, and cell survival, a function that is largely independent of its canonical role in ATP synthase. This discovery uncovers an unexpected link between a mitochondrial assembly factor and organellar dynamics, establishing the Atp12-Fzo1 axis as a conserved regulatory node that couples mitochondrial quality control to the aging process.
    Keywords:  Atp12; Fzo1; Schizosaccharomyces pombe; chronological lifespan; mitochondrial fusion
    DOI:  https://doi.org/10.1128/spectrum.02283-26
  12. Pharmacol Res. 2026 Nov 06. pii: S1043-6618(26)01658-0. [Epub ahead of print] 109743
      Nicotinamide adenine dinucleotide (NAD+) decline has been implicated in aging and age-related disease, and precursor supplementation with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) has shown efficacy in preclinical models. Human trials, however, have produced inconsistent functional outcomes, and the sources of this translational gap remain poorly defined. We combined a bibliometric analysis of 3,271 aging-focused NAD+ publications (2004-2025) with a critical synthesis of mechanistic and clinical evidence to localize where and why preclinical findings fail to translate. The bibliometric analysis revealed three structural features of the literature: (i) original research articles dominated the corpus, whereas the document-type classification cannot distinguish preclinical experiments from human observational or interventional studies; (ii) research is siloed across disease domains with limited cross-tissue comparison; and (iii) intervention-oriented keywords (NMN, NR, supplementation, drug delivery) have outpaced empirical clinical validation. Mechanistic synthesis showed that these structural gaps correspond to biological heterogeneity: NAD+ biosynthesis, consumption, redox balance, and subcellular compartmentalization are tissue- and compartment-specific, such that systemic precursor elevation does not uniformly restore functional NAD+ in disease-relevant tissues. Four subcellular pools-nuclear, cytosolic, mitochondrial, and axonal-each possess distinct rate-limiting bottlenecks, and hepatic metabolic reserve introduces an overlooked source of inter-individual variability. Across neurodegeneration, metabolic disease, cardiovascular aging, and sarcopenia, NAD+ dysregulation follows disease-specific mechanisms rather than a universal decline phenotype. We propose a precision-medicine framework that shifts the core question from whether NAD+ can be elevated to whether a defined intervention corrects a specific NAD+ defect in the appropriate tissue and subcellular compartment. This framework provides a structured basis for designing next-generation NAD+-targeted trials with tissue-specific biomarkers and function-oriented endpoints.
    Keywords:  NAD(+); NAD(+) precursors; aging; bibliometrics; clinical translation; mitochondrial function; precision medicine; sirtuins
    DOI:  https://doi.org/10.1016/j.phrs.2026.109743
  13. Cureus. 2026 Sep;18(9): e117236
      Chronic progressive external ophthalmoplegia (CPEO) is a rare manifestation of mitochondrial myopathy, marked by slowly progressive bilateral ptosis and ophthalmoplegia that can mimic other ocular myopathies, often leading to delayed diagnosis. We report a 63-year-old female with a 24-year history of slowly progressive bilateral ptosis, ophthalmoplegia, and proximal muscle weakness. Laboratory investigations, brain and orbital magnetic resonance imaging, and extensive genetic testing were unrevealing, and she did not respond to empirical treatment for presumed myasthenia gravis. Muscle biopsy demonstrated ragged red fibers, increased succinate dehydrogenase (SDH) activity, and cytochrome c oxidase (COX)-deficient fibers appearing intensely blue on combined SDH/COX staining, a pattern the authors term the "Blueberry Muffin Sign." Electron microscopy confirmed paracrystalline "parking lot" inclusions, supporting a diagnosis of CPEO due to mitochondrial myopathy. The "Blueberry Muffin Sign" on combined COX-SDH histochemical staining represents a potentially useful diagnostic clue for mitochondrial myopathy that may facilitate earlier recognition of CPEO, particularly when genetic testing is inconclusive; validation in larger, genetically characterized cohorts is needed to establish its diagnostic specificity and reproducibility.
    Keywords:  blueberry muffin sign; case report; mitochondrial myopathy; muscle biopsy; ophthalmoplegia
    DOI:  https://doi.org/10.7759/cureus.117236
  14. Nat Commun. 2026 Oct 07. pii: 11424. [Epub ahead of print]17(1):
      Mitochondria import hundreds of proteins into the matrix and the inner membrane (IM). The translocase of the IM of mitochondria (TIM23 complex) sorts these proteins using topogenic signals in their structure and directs them into the matrix or inserts them into the IM. How these signals are deciphered is unknown. Here we show that Tim17, the protein-conducting subunit of the TIM23 complex, contains a highly conserved selectivity filter for incoming proteins. Using a fluorescence-based sorting reporter, we identified the mitochondrial oxidoreductase Dmo2 (akin to DMAC1 in humans) as factor for intramitochondrial protein sorting. Molecular dynamics simulations show that a Dmo2-dependent disulfide bond into Tim17 constitutes a negatively charged selectivity filter at the vestibule of the TIM23 complex that arrests membrane proteins and facilitates the lateral insertion. Our work provides a molecular rationale as to how the TIM23 translocase differentiates between soluble and membrane proteins.
    DOI:  https://doi.org/10.1038/s41467-026-77990-3
  15. Genet Mol Biol. 2026 ;pii: S1415-47572026000500131. [Epub ahead of print]49Suppl 1(Suppl 1): e20260020
      Mitochondria are essential organelles in mammalian cells, performing multiple functions ranging from energy metabolism and intracellular signaling to the regulation of cell fate. Proper mitochondrial function depends on the coordinated expression of two distinct genomes: the nuclear genome and the mitochondrial genome, known as mitochondrial DNA (mtDNA). Although most mitochondrial proteins are encoded by nuclear genes, mtDNA encodes 13 polypeptides that are essential components of the oxidative phosphorylation (OXPHOS) system and ATP production. For reasons that are not yet fully understood, mtDNA accumulates DNA damage at levels estimated to be 1-5 times higher than those observed in nuclear DNA, underscoring the importance of efficient DNA repair and damage tolerance mechanisms within mitochondria. Mammalian mitochondria are competent in several DNA repair pathways, with base excision repair being the best characterized. However, the molecular mechanisms underlying DNA damage response (DDR) pathways activated by mtDNA lesions remain poorly defined. In this review, we briefly summarize the established DNA repair pathways operating in mammalian mitochondria, which have been extensively discussed elsewhere, and focus primarily on DDR components implicated in the response to mtDNA damage, as well as on the cellular consequences of mtDNA damage accumulation.
    DOI:  https://doi.org/10.1590/1678-4685-GMB-2026-0020
  16. Biochem Pharmacol. 2026 Nov 04. pii: S0006-2952(26)00937-8. [Epub ahead of print] 118594
      Migraine is a neurological disorder increasingly recognized as involving systemic and neuronal bioenergetic vulnerability - a state marked by cellular energy disruption, impaired mitochondrial function, and reduced ATP-generating capacity. Accumulating evidence implicates mitochondrial dysfunction and impaired oxidative phosphorylation as contributors to migraine pathophysiology, linking cellular energy deficits to cortical spreading depression, trigeminovascular activation, and oxidative stress. These pathophysiological mechanisms and related channelopathies shape the cellular energetic landscape. Under these conditions, metabolic disturbances influence symptom variability and phenotype heterogeneity, although the directionality of these relationships reflects a dynamic, bidirectional feedback loop between bioenergetic stress and migraine pathobiology. Here, we describe mechanisms by which limited energetic reserve modulates migraine onset, symptom evolution, and recovery. We review phase-specific bioenergetic shifts across the migraine cycle and highlight how these core cellular processes modulate network excitability. In parallel, we summarize key biomarkers, including calcitonin gene-related peptide and growth differentiation factor 15, together with related salivary or oral-fluid assays, which assist in multi-compartment biological profiling. This pathobiological axis interfaces with localized molecular signaling cascades, including pituitary adenylate cyclase-activating polypeptide signaling, sirtuin biology, microRNA-based and epigenetic regulation, and gene-informed mechanisms. This progression underscores a growing interest in molecular pathways governing neuronal energy balance and in exploratory metabolic and mitochondrial-supportive compounds. Together, these observations offer a mechanistic overview of migraine as a disorder where metabolic homeostasis affects expression, severity, and recovery - a framework that may inform future biomarker research and mechanistically targeted interventions, particularly in individuals with primary mitochondrial disease.
    Keywords:  Bioenergetics; Calcitonin gene-related peptide (CGRP); Cortical spreading depression (CSD); Growth differentiation factor 15 (GDF15); Migraine aura; Mitochondrial dysfunction; Mitochondrial syndromes (MELAS, MERRF, LHON, KSS); Molecular signaling pathways; Oxidative phosphorylation (OXPHOS); Oxidative stress; Salivary biomarkers; Trigeminovascular system
    DOI:  https://doi.org/10.1016/j.bcp.2026.118594
  17. J Biol Chem. 2026 Nov 04. pii: S0021-9258(26)02600-1. [Epub ahead of print] 113728
      The adenine nucleotide translocator (ANT) is essential for cellular energy metabolism, mediating the exchange of ADP and ATP across the inner mitochondrial membrane. While mammals express multiple ANT isoforms, it remains unclear whether they possess distinct properties or whether their diverse expression patterns reflect functional specialization as widely posited. In this study, we employed a controlled human cell system to directly compare the transport kinetics and bioenergetic contributions of individual human ANT isoforms. By evaluating endogenous knockout cells and systematically re-expressing each isoform, we demonstrate that ANT1, ANT2, and ANT3 are functionally redundant. The three ANT isoforms exhibited near-identical transport rates in both forward (ADPin/ATPout) and reverse (ATPin/ADPout) exchanges. While transport kinetics were equivalent, cells solely expressing ANT2 or ANT3 exhibited slightly different resilience to respiratory inhibition, suggesting isoform-specific roles that may be related to non-transport functions. Our findings provide a refined view of ANT-mediated mitochondrial nucleotide flux and suggest that ANT isoform-specific differences, if they exist, are likely subtle and not innately tied to ADP/ATP exchange.
    Keywords:  ADP; ATP; bioenergetics; exchanger; mammal; membrane protein; mitochondria; mitochondrial transport
    DOI:  https://doi.org/10.1016/j.jbc.2026.113728
  18. Nat Commun. 2026 Oct 09. pii: 11476. [Epub ahead of print]17(1):
      Pediatric mitochondrial disease (PMD) is challenging due to its genetic heterogeneity, diagnostic difficulty, and unpredictable trajectories. Current biomarkers lack sensitivity to diagnose PMD or predict its severe course. Here, we show a multi-omics framework with longitudinal monitoring to resolve these challenges. We identify metabolic and transcriptomic dysregulation in PMD, deriving a robust 7-feature multi-omics diagnostic panel (6 metabolites, 1 transcript). In an independent validation cohort, this panel achieved superior diagnostic accuracy (AUC = 0.96) compared to conventional biomarkers. Beyond diagnosis, we addressed the need for patient stratification. Unsupervised proteomic clustering revealed two subtypes (Cluster I and II) that diverged over time; Cluster II patients had downregulation of cytoskeletal and immune pathways and worse clinical outcomes at 12 months. We leveraged these insights to develop a 12-transcript prognostic signature that predicts clinical prognostication with high accuracy (AUC = 0.85). This study establishes a molecular framework for PMD, offering validated tools for precision diagnosis and prognostic stratification.
    DOI:  https://doi.org/10.1038/s41467-026-78387-y
  19. Exp Gerontol. 2026 Nov 06. pii: S0531-5565(26)00362-1. [Epub ahead of print] 113382
      Sarcopenia is characterized by progressive loss of skeletal muscle strength, mass, and function during aging, driven by impaired proteostasis, mitochondrial dysfunction, altered metabolism, regenerative failure, and neuromuscular decline. Experimental models are needed to determine how these processes drive muscle degeneration and identify testable therapeutic mechanisms. Zebrafish combine whole-animal physiology with genetic manipulation, live imaging, and scalable phenotypic analysis, making them well suited to this purpose. Natural-aging, telomerase-deficient, dexamethasone-induced, high-fat-diet, and genetically defined zebrafish models each reproduce distinct structural, functional, metabolic, regenerative, or neuromuscular changes relevant to sarcopenia. In this Review, we compare study designs, measured endpoints, and mechanistic evidence to distinguish age-associated phenotypes from responses to induced stresses or defined molecular perturbations. Natural-aging models capture spontaneous age-associated changes in muscle structure, performance, and mitochondrial integrity; telomerase-deficient models reveal defects in tissue maintenance and regeneration; and dexamethasone- and high-fat-diet-induced models enable controlled analysis of proteostatic and metabolic stress. Genetic models directly test relationships between molecular perturbations and muscle phenotypes. Current studies, however, have notable limitations: swimming performance reflects whole-animal physiology rather than muscle strength, many markers do not directly measure pathway activity, and some models represent specific stress rather than primary sarcopenia. Across these models, shared phenotypes do not establish a common causal mechanism; model-specific findings require validation during natural aging and in mammalian and human studies.
    Keywords:  Mitochondria; Muscle regeneration; Neuromuscular junction; Sarcopenia; Skeletal muscle aging; Zebrafish
    DOI:  https://doi.org/10.1016/j.exger.2026.113382
  20. Pharmaceut Med. 2026 Nov 03.
       BACKGROUND AND OBJECTIVE: The European Medicines Agency (EMA) PRIority MEdicines (PRIME) scheme supports the development of medicines addressing unmet medical needs through early scientific and regulatory guidance. The aim of this study was to describe the regulatory pathways and pivotal trial characteristics of PRIME-designated medicines that received a positive Committee for Medicinal Products for Human Use (CHMP) opinion between 2018-2024.
    METHODS: In this retrospective descriptive analysis, public EMA documents were reviewed. Extracted variables included regulatory characteristics (orphan drugs designation, advanced therapy medicinal products, new active substances, accelerated assessment, conditional marketing authorisation, exceptional circumstances and withdrawals), procedural timelines and pivotal trial features (phase, randomisation, blinding, comparator, number of arms, sample size and objectives). The analysis was conducted in two parts. In the first part, medicine was the unit of analysis to describe characteristics and regulatory pathways. In the second part, the unit of analysis was the medicine-indication pair defined as a unique combination of a medicine and an authorised indication and used to describe the main studies on which the CHMP based its positive opinion. Different indications for the same medicine were analysed separately when supported by distinct evidence packages, whereas indications supported by a common evidence package were analysed jointly to avoid double counting. Categorical variables were expressed as frequencies and proportions. Time intervals were calculated in calendar days and summarised as medians with interquartile range (IQR).
    RESULTS: Thirty-six PRIME-designated medicines received a positive CHMP opinion between 2018 and 2024. Oncology was the most frequent therapeutic area (12/36, 33.3%), followed by haematology-haemostaseology (8/36, 22.2%). The median time from PRIME eligibility to marketing authorisation application (MAA) submission was 844 calendar days (IQR 644-1259). Accelerated assessment (AA) was requested for 32 of the 36 medicines (88.9%). Although 27 of these requests were initially approved by the CHMP and/or the Committee for Advanced Therapies (CAT), 15 were later reverted to the standard review timeline during the assessment process. As a result, only 12 of the applications underwent AA. The median time from the start of the regulatory assessment to receipt of a positive CHMP opinion was 263.5 calendar days (IQR 201.3-325.3). Nineteen medicines received conditional marketing authorisation (CMA) (19/36, 52.8%) and two were authorised under exceptional circumstances (5.6%). Of the 36 medicines, 33 received a positive CHMP opinion for a single indication and 3 for two indications, resulting in 39 medicine-indication pairs. A total of 58 pivotal/main studies were identified from European Public Assessment Reports (EPARs) across the 39 medicines-indication pairs. The median sample size was 74.5 patients (IQR 33-161), and studies were predominantly open-label (45/58, 77.6%) and single-arm (35/58, 60.3%). By the end of 2025, among the 19 medicines initially granted a CMA, 11 medicines (57.9%) remained under CMA and 5 (26.3%) had been converted to standard marketing authorisations. Four medicines were subsequently withdrawn from the EU market.
    CONCLUSION: Approval of PRIME-designated medicines in the EU was frequently based on non-randomised and non-comparative evidence, with CMA. The evaluation process was expedited for a minority of the products applied. The findings reflect the challenges of evidence generation for rare and serious diseases with unmet medical needs and underscore the importance of post-authorisation evidence generation.
    DOI:  https://doi.org/10.1007/s40290-026-00642-w
  21. Mol Neurobiol. 2026 Oct 31. pii: 1007. [Epub ahead of print]63(1):
      Maintenance of protein homeostasis is essential for neuronal survival, and its disruption is a defining feature of neurodegenerative diseases. Neurons are particularly vulnerable to proteostatic stress due to their post-mitotic nature, long lifespan, and dependence on cytoskeletal integrity for structural stability, intracellular transport, and synaptic function. In tauopathies and related neurodegenerative disorders, misfolded proteins and aggregation-prone proteins burden the cellular quality-control systems, leading to cytoskeletal destabilization, synaptic dysfunction, and progressive neuronal loss. This review is organized around a central question: for a given tau species, defined by its isoform, post-translational modifications, and assembly state, what determines its fate? We examine how molecular chaperone networks, including HSP100, HSP90, HSP70, J-domain proteins (JDPs), small heat shock proteins (sHSPs), and the Prefoldin-CCT pathway, regulate the folding, disaggregation, sequestration, and degradation of pathogenic tau. We highlight how these chaperone networks influence key proteostasis checkpoints, determine whether tau refolds, is degraded, or is redirected toward toxic aggregation, and how these outcomes impact microtubule stability and neuronal function. Drawing on studies in yeast, Drosophila, mammalian models, and human tissues, we develop two key conclusions. First, chaperone activity is not uniformly protective against tauopathies; its effects depend on the tau species, cellular context, and disease stage. Second, because the cytoskeleton is both a chaperone client and an essential component of intracellular clearance pathways, tau pathology and proteostasis failure can reinforce one another. Finally, we discuss emerging therapeutic strategies and challenges in targeting chaperone networks to restore proteostasis while avoiding unintended neurotoxic consequences.
    Keywords:  Cytoskeletal dysfunction; Heat shock proteins; Molecular chaperones; Protein aggregation; Proteostasis; Tauopathy
    DOI:  https://doi.org/10.1007/s12035-026-06310-z
  22. J Nurs Manag. 2026 ;pii: e5143378. [Epub ahead of print]2026(1):
       BACKGROUND: Nurses provide pediatric and neonatal palliative care amid substantial emotional and relational demands. Qualitative evidence remains fragmented on how nurses sustain compassionate care and how relational and organizational conditions shape these efforts. This systematic review and meta-synthesis examined these experiences across palliative and end-of-life settings.
    METHODS: PubMed, CINAHL, Embase, PsycINFO, Web of Science, and Scopus were searched from inception to September 2026. Qualitative studies and separately extractable qualitative components of mixed-methods studies addressing nurses' experiences of pediatric or neonatal palliative care were eligible. Two reviewers independently screened records, extracted data, and applied the Joanna Briggs Institute qualitative appraisal checklist. Findings were synthesized using Thomas and Harden's three-stage thematic synthesis, with confidence assessed using GRADE-CERQual.
    RESULTS: Thirty-seven studies from 21 countries reported a total of 599 nursing participants. Four analytical themes and 18 descriptive subthemes were generated: (1) finding meaning through care for children and families; (2) managing relational closeness and professional boundaries; (3) responding to grief and loss through coping and meaning-making; and (4) seeking and using interpersonal and organizational support. Confidence was moderate for Themes 1-3 and high for Theme 4. Valued care, relational involvement, coping, and support coexisted with persistent grief, emotional depletion, and unmet needs.
    CONCLUSIONS: Nurses' efforts to sustain compassionate care involve interacting personal, relational, and organizational processes. Meaningful care can coexist with persistent grief and emotional strain, with variation in emotional availability and recovery. These findings highlight the importance of organizational support alongside individual coping.
    IMPLICATIONS FOR NURSING MANAGEMENT: Managers should protect time and resources for relational care and strengthen nursing participation in interdisciplinary decisions. Emotional and clinical support should be accessible and responsive to nurses' preferences, including opportunities for reflection, supervision, and peer support.
    Keywords:  coping; meaning-making; neonatal palliative care; nurses; pediatric palliative care; professional boundaries; qualitative meta-synthesis
    DOI:  https://doi.org/10.1155/jonm/5143378
  23. Front Genet. 2026 ;17 1881863
       Background: Harel-Yoon syndrome (HAYOS) is a rare neurometabolic disorder caused by pathogenic variants in the ATAD3A gene, a key regulator of mitochondrial dynamics and cellular homeostasis. Although a broad phenotypic spectrum has been described, the relationship between genotype and long-term functional outcomes remains incompletely understood.
    Case Presentation: We report two adult sisters with genetically confirmed HAYOS who exhibited early-onset hypotonia progressing to spasticity, craniofacial dysmorphism, optic atrophy, and sensorimotor polyneuropathy. Neuroimaging revealed mild cerebellar atrophy, and electrophysiological studies showed a chronic sensorimotor polyneuropathy with axonal loss and conduction slowing. Initial exome sequencing revealed a variant of uncertain significance in COL5A1, whereas subsequent targeted familial Sanger sequencing confirmed the heterozygous ATAD3A NM_001170535.3:c.1582C>T (p.Arg528Trp) variant in both sisters. Parental segregation could not be assessed because their father died before genetic evaluation and their mother declined further clinical evaluation and targeted segregation testing for the familial ATAD3A variant. Despite severe progressive motor impairment leading to wheelchair dependence, both patients completed formal education and had low-average IQ scores (88 and 82) at single adult assessments.
    Conclusion: These cases expand the phenotypic spectrum of HAYOS by demonstrating that severe progressive motor disability may coexist with relative cognitive preservation at adult assessment, limited cardiac or metabolic involvement, and long-term survival. Our findings highlight the diagnostic challenges posed by the ATAD3 locus and underscore the importance of comprehensive genetic evaluation in suspected mitochondrial disorders. Rather than representing a globally mild phenotype, these patients show a motor-severe but cognitively and systemically attenuated presentation, with implications for prognosis, genetic counseling, and clinical management.
    Keywords:  ATAD3A; Harel–Yoon syndrome; case report; genotype–phenotype correlation; mitochondrial disease
    DOI:  https://doi.org/10.3389/fgene.2026.1881863
  24. Placenta. 2026 Oct 24. pii: S0143-4004(26)00728-9. [Epub ahead of print]186 223-232
       BACKGROUND: In Preeclampsia (PE), the mechanisms linking placental injury to maternal vascular inflammation remain incompletely understood. Circulating cell-free mitochondrial DNA (ccf-mtDNA), released from damaged or ischemic placental mitochondria, may function as a damage-associated molecular pattern and activate Toll-like receptor 9 (TLR9).
    METHODS: In this case-control study, 150 women with PE, 150 non-PE pregnant women, and 50 non-pregnant women were evaluated. Plasma ccf-mtDNA copy number was quantified by quantitative real-time PCR targeting mitochondrial ND1 gene and normalised to 36B4. Placental TLR9 expression was assessed by qRT-PCR and immunohistochemistry (n = 10/group). Human placental vascular endothelial cells (HPVECs) were treated with a TLR9 agonist (ODN 2395), antagonist (ODN A151), or plasma from PE and non-PE women (n = 10/group). Protein carbonylation, lipid peroxidation, and secretion of IL-6, TNF-α, and IL-10 were assessed.
    RESULTS: Plasma ccf-mtDNA copy number was significantly higher in PE than in non-PE pregnant and non-pregnant women, showing a progressive stepwise increase across groups (p < 0.001). Placental TLR9 mRNA and protein expression were significantly increased in PE (p ≤ 0.0013). TLR9 agonism significantly increased protein carbonylation, malondialdehyde, IL-6, TNF-α, and IL-10 in HPVECs (all p < 0.0001). PE plasma produced similar effects, which were significantly attenuated by TLR9 antagonism (p < 0.05). Responses to non-PE plasma were weaker and less consistently inhibited by TLR9 blockade.
    CONCLUSIONS: PE is associated with increased circulating mitochondrial DNA and placental TLR9 expression. The findings support a potential ccf-mtDNA-TLR9 pathway linking placental mitochondrial injury to endothelial oxidative stress and inflammatory responses, suggesting TLR9-mediated innate immune activation as a potential mechanistic and therapeutic target in PE.
    Keywords:  Circulating cell-free mitochondrial DNA; Endothelial dysfunction; Oxidative stress; Placenta; Preeclampsia; Toll-like receptor 9
    DOI:  https://doi.org/10.1016/j.placenta.2026.10.011
  25. Proc Natl Acad Sci U S A. 2026 Nov 17. 123(46): e2605454123
      Biological aging is complex and resists any single mechanistic narrative. This article develops a conceptual framework for aging biology through a series of brief statements on central topics in the field, with the goal of discussing aging simply, directly and accessibly. The organizing principle is that aging is a default outcome of living: because biological processes are inherently imperfect, deleterious changes (the deleteriome) accumulate over time and progressively erode functional reserve. The deleteriome provides a unifying framework for molecular damage, regulatory drift, maladaptive remodeling, and system-level failure, without reducing aging to individual genes, pathways, compartments, hallmarks, or pathologies. Evolution does not program aging; it shapes maintenance and renewal systems that oppose this trajectory with limited fidelity and unavoidable trade-offs. Aging begins during development, following an early embryonic phase of rejuvenation. Modern biomarkers make biological age imperfectly but increasingly measurable. Biological age is heterogeneous across cells, organs, and systems, modifiable by interventions and environment, and in some contexts partially reversible or resettable, although aging itself is irreversible. This model links first principles of aging to measurement, intervention, and longer-term strategies, with the goal of clarifying how substantial longevity gains might be achieved, both within and beyond existing species-level constraints.
    Keywords:  aging; aging clocks; biological age; interventions; lifespan
    DOI:  https://doi.org/10.1073/pnas.2605454123
  26. Autophagy. 2026 Nov 04.
      PHB2 (prohibitin 2), a well-known inner mitochondrial membrane mitophagy receptor, has recently emerged as a potential sensor of intracellular bacteria. A recent study shows that increased exposure of the inner mitochondrial membrane protein PHB2 enables its interaction with bacterial surface proteins and the recruitment of the E3 ubiquitin ligases ARIH1 (ariadne RBR E3 ubiquitin protein ligase 1) or PRKN (parkin RBR E3 ubiquitin protein ligase), thereby promoting xenophagy. This finding expands the role of damaged mitochondria from autophagic cargo to an active platform for antibacterial defense. It also raises broader questions regarding how an inner mitochondrial membrane protein becomes accessible to invading bacteria, why PHB2 can recognize bacterial proteins, and what determines whether exposed PHB2 promotes mitophagy, xenophagy, or co-degradation of both cargos. Here, we discuss PHB2 as a potential damage-unmasked bacterial sensor, the contribution of mitochondrial membrane remodeling to its exposure, and the evolutionary relationship between mitochondrial and bacterial recognition. We further consider whether impaired mitophagy may compromise xenophagic competence in aging and disease.
    Keywords:  Innate immunity; PHB2; mitochondrial membrane; mitophagy; xenophagy
    DOI:  https://doi.org/10.1080/15548627.2026.2759481